Sponsors (12)
The bill improves clarity, coordination, and incentives to accelerate ALS and other rare neurodegenerative therapy development — potentially speeding patient access and aiding researchers — but it raises costs, administrative burdens, confidentiality concerns, and funding/timing risks if resources and safeguards are not secured.
Patients with rare diseases (including ALS) could gain clearer and expanded pathways to therapies because the bill reauthorizes program authority, links renewals to trial progress, and requires a public 5‑year FDA plan to speed development.
Researchers, trial sponsors, and drug developers will get clearer eligibility and planning signals — e.g., broadened definitions, confirmation that phase 2/3 and planned phase 3 trials count as participating clinical trials, and FDA resource estimates — improving grant access and trial planning.
HHS/FDA oversight and public accountability for rare disease drug development should improve because grant renewals can rely on interim trial data and the agency must publish a 5‑year action plan and progress assessments.
Taxpayers could face increased federal costs if the bill expands or reauthorizes programs without offsetting savings or appropriations.
Implementing new statutory language, preparing the required reports/plans, and handling additional oversight could increase administrative burden and divert FDA/HHS staff time from other regulatory work, delaying some activities.
Requiring interim trial data for renewals raises confidentiality and intellectual property concerns and adds reporting burdens that may deter some sponsors (especially small businesses) from applying for grants.
Based on analysis of 5 sections of legislative text.
Reauthorizes and amends the ALS Act to expand qualifying trial definitions, allow FDA review of enrollment/interim data for grant renewals, and require a public 5‑year FDA action plan and assessment.
Revises and reauthorizes parts of the Accelerating Access to Critical Therapies for ALS Act to clarify which clinical trials count for grant purposes, allow FDA to consider trial enrollment and request interim trial data when renewing grants, and require the FDA to publish an updated five-year action plan and assessment of its 2022 Action Plan for rare neurodegenerative diseases (including ALS). The bill strikes and replaces portions of the underlying law and inserts new reporting and definitional language to guide grant reviews and regulatory planning. The changes affect statutory grant authority and definitions (21 U.S.C. § 360ee and related provisions), expand the statutory definition of “participating clinical trial” to include combined phase 2/3 and planned phase 3 trials, and direct the FDA Commissioner to post a public website report with an updated 5‑year plan and an assessment of prior actions within one year of enactment.
Official title: Amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Introduced April 30, 2026 by Lisa Murkowski · Last progress April 30, 2026